Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations
PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulationsPsyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facilityPULL operates best-in-class processing infrastructure under Standard Processing License by Health CanadaNear term milestones include Canada-based human clinical trials Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction…